ProfileGDS5678 / 1430535_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 92% 92% 89% 91% 93% 94% 91% 91% 92% 93% 92% 92% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.7315593
GSM967853U87-EV human glioblastoma xenograft - Control 27.7173492
GSM967854U87-EV human glioblastoma xenograft - Control 37.7140892
GSM967855U87-EV human glioblastoma xenograft - Control 47.2319989
GSM967856U87-EV human glioblastoma xenograft - Control 57.4053191
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.5857593
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.8371494
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.4287491
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.296991
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.5551992
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.7345793
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.6505692
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.5961592
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.6158192